Multiple-sclerosis therapies · Alzheimer's therapies · Biosimilars
Biogen
A biopharmaceutical company developing treatments for multiple sclerosis, Alzheimer's, and other neurological diseases. S&P 500 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
BIIB Updated Jul 11, 2026 2 AI consumers· 2 recurring
Annual return · 2026-09-04'21-2%'22+15.4%'23-6.6%'24-40.9%'25+15.1%YTD+25.5%
Money in ▸·
Biogen~$9.7B
▸ Money out·
Financials & Segments
- Total revenue · ~$9.7B (FY2024)
- Segments · Multiple Sclerosis · Alzheimer's & New Products · Biosimilars
Revenue from
No refined links yet.
Pays to
No refined links yet.